Stephen P. Squinto - May 19, 2022 Form 4 Insider Report for SpringWorks Therapeutics, Inc. (SWTX)

Role: Director, 10%+ Owner
Signature: /s/ Francis I. Perier, Jr as Attorney-in-Fact
Stock symbol: SWTX
Transactions as of: May 19, 2022
Transactions value $: $0
Form type: 4
Date filed: 5/20/2022, 05:44 PM
Previous filing: Feb 23, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SWTX	Common Stock	Award	$0	+4.82K	+3.8%	$0.00	132K	May 19, 2022	Direct	F1
holding	SWTX	Common Stock						6.19M	May 19, 2022	See Footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SWTX	Stock Option (Right to Buy)	Award	$0	+15.3K		$0.00	15.3K	May 19, 2022	Common Stock	15.3K	$35.42	Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction represents a grant of restricted stock units ("RSUs") pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders. The RSUs shall vest in full on the earlier of (1) May 19, 2023 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person.
F2	Shares held by OrbiMed Private Investments VI, LP ("OrbiMed VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OrbiMed VI. OrbiMed Advisors, LLC ("Advisors") is the managing member of GP VI. By virtue of such relationship, GP VI and Advisors may be deemed to have voting and investment power with respect to the shares held by OrbiMed VI and as a result may be deemed to have beneficial ownership of such shares. The reporting person is an Executive Partner at Advisors. This report shall not be deemed an admission that the reporting person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F3	This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders.
F4	The options shall vest in full on the earlier of (1) May 19, 2023 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person.